Pfizer Inc. Files 8-K Report
Ticker: PFE · Form: 8-K · Filed: Dec 17, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: PFE
TL;DR
Pfizer filed an 8-K on 12/17/24, mostly standard disclosures.
AI Summary
On December 17, 2024, Pfizer Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific new financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Pfizer is providing updated information to the SEC, which could include financial disclosures or other material events relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for disclosures and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- December 17, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 13-5315170 (identification_number) — I.R.S. Employer Identification No.
- 66 Hudson Boulevard East (address) — Principal executive offices
- New York, New York (location) — Principal executive offices
- 10001-2192 (zip_code) — Principal executive offices
- ( 212 ) 733-2323 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Pfizer Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on December 17, 2024.
In which state was Pfizer Inc. incorporated?
Pfizer Inc. was incorporated in Delaware.
What is the principal executive office address for Pfizer Inc.?
The principal executive office address is 66 Hudson Boulevard East, New York, New York, 10001-2192.
What is Pfizer Inc.'s telephone number as listed in the filing?
Pfizer Inc.'s telephone number is (212) 733-2323.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-12-17 07:47:10
Filing Documents
- pfe-20241217.htm (8-K) — 33KB
- pfe-12172024xexh99.htm (EX-99.1) — 88KB
- pfizerlogoa.jpg (GRAPHIC) — 38KB
- 0000078003-24-000195.txt ( ) — 343KB
- pfe-20241217.xsd (EX-101.SCH) — 3KB
- pfe-20241217_def.xml (EX-101.DEF) — 15KB
- pfe-20241217_lab.xml (EX-101.LAB) — 27KB
- pfe-20241217_pre.xml (EX-101.PRE) — 16KB
- pfe-20241217_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 17, 2024, Pfizer Inc. issued a press release that provided its full-year 2025 guidance and reaffirmed its full-year 2024 financial guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information furnished pursuant to this "Item 7.01 – Regulation FD Disclosure", including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description Exhibit 99.1 Press Release of Pfizer Inc. dated December 17, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: December 17, 2024